- Home
- FTHY vs CSTL Comparison
FTHY vs CSTL Comparison
Compare FTHY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- CSTL
- Stock Information
- Founded
- FTHY 2020
- CSTL 2007
- Country
- FTHY United States
- CSTL United States
- Employees
- FTHY N/A
- CSTL N/A
- Industry
- FTHY Investment Managers
- CSTL Medical Specialities
- Sector
- FTHY Finance
- CSTL Health Care
- Exchange
- FTHY Nasdaq
- CSTL Nasdaq
- Market Cap
- FTHY 500.1M
- CSTL 561.9M
- IPO Year
- FTHY N/A
- CSTL 2019
- Fundamental
- Price
- FTHY $14.72
- CSTL $16.43
- Analyst Decision
- FTHY
- CSTL Strong Buy
- Analyst Count
- FTHY 0
- CSTL 6
- Target Price
- FTHY N/A
- CSTL $37.67
- AVG Volume (30 Days)
- FTHY 176.7K
- CSTL 425.9K
- Earning Date
- FTHY 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- FTHY 10.93%
- CSTL N/A
- EPS Growth
- FTHY N/A
- CSTL N/A
- EPS
- FTHY N/A
- CSTL N/A
- Revenue
- FTHY N/A
- CSTL $347,083,000.00
- Revenue This Year
- FTHY N/A
- CSTL N/A
- Revenue Next Year
- FTHY N/A
- CSTL $1.36
- P/E Ratio
- FTHY N/A
- CSTL N/A
- Revenue Growth
- FTHY N/A
- CSTL 38.43
- 52 Week Low
- FTHY $12.66
- CSTL $15.45
- 52 Week High
- FTHY $14.74
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- FTHY 56.93
- CSTL 33.31
- Support Level
- FTHY $14.62
- CSTL $16.16
- Resistance Level
- FTHY $14.87
- CSTL $17.31
- Average True Range (ATR)
- FTHY 0.11
- CSTL 0.82
- MACD
- FTHY -0.01
- CSTL -0.41
- Stochastic Oscillator
- FTHY 59.46
- CSTL 6.50
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.